Tatva Chintan Pharma Chem Limited — Q1 FY26 earnings call

Call held 24 Jul 2025

Management summary

Tatva Chintan delivered a strong Q1 FY26, with operating revenue growing 11% YoY to INR 1,169 million and EBITDA surging 37% YoY to INR 173 million, driven by robust performance in PASC and SDA segments. The company is optimistic about future growth from new product commercializations and Euro 7 norms for SDA, despite persistent geopolitical uncertainties and the announced departure of its CFO.

Highlights

  • Operating revenue of INR 1,169 million, registering an 11% increase year-on-year and a healthy 8% growth over the previous quarter.

  • EBITDA came in at INR 173 million, reflecting a 37% year-on-year rise and a notable 94% growth as compared to previous quarter.

  • EBITDA margin increased by 287 bps year-on-year basis to 14.8%.

  • Pharma & Agro Intermediates and Specialty Chemicals (PASC) delivered INR 432 million in revenue, up 32% sequentially and 11% year-on-year.

  • Structure Directing Agents (SDA) recorded a revenue of INR 394 million with a 14% growth quarter-on-quarter and a 13% improvement year-on-year.

  • Semiconductor segment achieved successful supply of pilot scale samples meeting customer requirements, generating strong interest from leading companies.

Concerns

  • CFO, Mr. Ashok Bothra, has decided to relocate himself and pursue another opportunity.

  • Phase Transfer Catalyst (PTC) contributed INR 323 million in revenue, marking a 17% decline on a quarterly basis.

  • Global geopolitical landscape remains fragile and uncertainties persist pertaining to U.S. reciprocal tariffs.

  • SDA pricing still continues to remain at non-viable levels due to cheap raw materials.

Key financials

  1. Revenue from Operations 1,168 Mn +10.7%YoY
  2. Other Income 11 Mn
  3. EBITDA 173 Mn +37.3%YoY
  4. EBITDA Margin 14.8%
  5. PBT 91 Mn
  6. PAT 66 Mn +26.9%YoY
  7. PAT Margin 5.7%
  8. EPS ₹2.84
  9. Exports 830 Mn
  10. Exports Contribution 71%

What they filed

Q1 FY27: revenue up 42.7%, net profit up 128.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue83 86 108 117 124 +49%131 +52%134 +24%167 +43%
EBITDA6 7 9 17 22 +267%25 +257%28 +211%32 +88%
Net profit-1 0 1 7 10 +1100%15 10 +900%16 +129%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
1,161 Mn Total
  • Pharma & Agro Intermediates and Specialty Chemicals 432 Mn 37.2%
  • Structure Directing Agents 394 Mn 33.9%
  • Phase Transfer Catalyst 323 Mn 27.8%
  • Electrolyte Salts 12 Mn 1.0%

Capital allocation

medium confidence
  • Capex ₹110 Cr
    • New block for agro intermediates
    • Additional capex for high potential agro intermediate at Jolva greenfield facility
    • Small modifications/modified area for semiconductor pilot scale production
    Chintan Shah: "It's about INR110 crores." (page 8); "We have a new block coming up. So that is to accommodate the missing parts which we require to achieve the full volumes that the customer wants for the new agro intermediates. This is within the same site, a new block within the same site." (page 10); "The production of this product will require additional capex, which we plan to undertake at our upcoming greenfield facility in Jolva." (page 5); "Even within our existing facility, we will have to undergo a lot of modifications and changes to be able to, so right now, whatever infrastructure is in place is to only make this level of products at a pilot scale." (page 9)

Guidance & targets

Revenue

  • Revenue Growth Revenue · FY26 · High confidence upward of 25%
    It will be a forward-looking statement. So, for '25, '26, we have given a guidance of upward of 25%.

    — Ashok Bothra

  • Revenue Growth Revenue · FY27 · Medium confidence 20% to 25%
    Probably another 20% to 25% growth is what we are looking at for the next financial year compared to where we end this year.

    — Chintan Shah

Margin

  • EBITDA Margin Margin · FY26 · High confidence 20%
    Yes. That is what we will see in the coming quarters. Yes. We stay with the forecast, and it is happening. And we have very clear visibility at least in December. So, there is no favouring from our forecast that is going to happen.

    — Chintan Shah

  • EBITDA Margin Margin · FY27 · Medium confidence 20%
    About similar, 20% level.

    — Chintan Shah

Segment Contribution

  • Electrolyte Salts Contribution to Top Line Segment Contribution · next financial years · Medium confidence 10%
    I would say roughly about 10%.

    — Chintan Shah

Segment Revenue

  • Electrolyte Salts Revenue Segment Revenue · Medium confidence INR 15-20 crores
    More or less, yes. Anywhere between INR15 crores to INR20 crores.

    — Chintan Shah

Volume Growth

  • SDA Volume Growth Volume Growth · High confidence 40% to 70%
    We are sticking on to that. Maybe a quarter plus or minus, but we are sticking on to that.

    — Chintan Shah

Commercialization Timeline

  • Semiconductor Commercialization Commercialization Timeline · 2027-2029 · High confidence 2027 (slow) to 2029 (full-scale)
    We expect a slow commercialization to begin in 2027, leading to a full-scale commercialization in 2029.

    — Chintan Shah

  • PASC Commercialization (Agro Intermediate) Commercialization Timeline · Q3 FY26 · High confidence November
    Basically, now we are definitely into the commercialization mode, beginning supplies from November.

    — Chintan Shah

  • Pharma Intermediate Commercialization Commercialization Timeline · FY27 · High confidence August or September of 2026
    Typically, we expect somewhere in August or September of 2026 when we expect to start commercializing these products.

    — Chintan Shah

Regulatory Impact

  • Euro 7 Implementation Regulatory Impact · 2027 · High confidence 2027 beginning
    2027 beginning.

    — Chintan Shah

What to watch in Q2 FY26

SDA Volume Growth

next quarter
Current picking up, stronger demand coming in Q2 and Q3
Target 40% to 70% growth in volume

Why it matters

Key indicator of SDA segment recovery and overall revenue growth, as management reaffirmed this target.

We are sticking on to that. Maybe a quarter plus or minus, but we are sticking on to that.

Risks & concerns

  • Global geopolitical landscape and US reciprocal tariffs

    medium

    Geopolitical landscape remains fragile and uncertainties persist regarding U.S. reciprocal tariffs, though current products are not subject to them.

    Management acknowledged

  • SDA pricing at non-viable levels

    medium

    SDA pricing continues to remain at non-viable levels due to cheap raw materials, impacting value realization.

    Management acknowledged

  • CFO transition

    low

    Mr. Ashok Bothra, the CFO, is relocating and pursuing another opportunity.

    Management acknowledged

  • Teething issues in PASC production

    low

    As production volumes enhance, some teething issues are being resolved and gradually moving towards smooth production cycles.

    Management acknowledged

Q&A highlights

8 direct
SDA Pricing and Volume Demand Direct
the first answer to your the pricing part, pricing still remains to be at the same levels as last year. There is no significant change in chemical pricing on the raw material front. So, the price of our SDA still continues to remain at the same level. In terms of demand, still the Chinese demand is nearly negligible, whereas the U.S. and the Europe demands have actually picked up.

Clarifies the current state of SDA pricing and demand drivers, indicating a shift away from China and towards Western markets.

Asked by Sudarshan Padmanabhan

SDA Volume Growth Guidance Direct
We are sticking on to that. Maybe a quarter plus or minus, but we are sticking on to that.

Reaffirms management's confidence in achieving previously stated aggressive volume growth targets for the SDA segment.

Asked by Sudarshan Padmanabhan

PASC New Launches and Existing Product Momentum Direct
So as far as the existing products are concerned, there is a very marginal increase in terms of demand that is happening. With respect to the new launches, we have significant developments in terms of orders received for beginning from Q3 and we expect that to continue, because the next financial as per their customers' financial year, it will begin in early 2026.

Highlights that future growth in PASC will primarily be driven by new product launches rather than existing ones, with orders already secured for Q3.

Asked by Sudarshan Padmanabhan

Semiconductor Applications and Capex Requirements Direct
In terms of capex requirement, our existing plant can only cater to a very small volume. So, it could be a start-up for the overall demand. And as I said during my address, it's going to be fully commercialized by 2029 is what is the deadline we expect. So, though we will have some significant volumes beginning from 2027.

Provides clarity on the long-term capex needs and commercialization timeline for the high-potential semiconductor segment, indicating a phased approach.

Asked by Varun Mohanraj

Electrolyte Business Peak Revenue and Margin Direct
So, if I assume correctly, maybe in the existing facility, we may get revenue close to about INR100 crores from this. But ultimately, we'll have to look at further expansions at our new Jolva site. ... So, these are, again, as good in terms of margins as our SDA segment.

Quantifies the potential revenue from the existing electrolyte facility and indicates strong margin potential, comparable to the SDA segment.

Asked by Varun Mohanraj

Delay in Pharma Intermediate Commercialization Direct
I am at supplier, Stage 1, I supply this to supplier, Stage 2; and then they make something and supply it to the final API manufacturer. So, the delay is actually happening at the Stage 2 supplier where they have some delays in their capex, so which is causing basically delays in the overall validation of our materials.

Explains the reason for the delay in commercialization of pharma intermediates, attributing it to external factors in the supply chain rather than internal issues.

Asked by Sanjesh Jain

Total Addressable Market for SDA Direct
SDA has lot of different applications. We primarily cater to our largest segments come from applications into automotive gas emission purification. And second is into the petrochemical applications. So, with these 2, I would believe still we are at about 20%-odd in terms of addressable market where we stand right now.

Provides insight into the current market penetration and future growth potential for SDA, highlighting untapped segments due to infrastructure limitations.

Asked by Raman KV

Optimism for China Diesel Engine Demand Rebound Direct
the industry is expecting the shift to happen within a couple of quarters when we again see a rebound of diesel engines coming back in China. So, this is how it looks like so far.

Addresses a key market dynamic, explaining the rationale behind the expectation of a recovery in diesel engine demand in China, which is relevant for SDA.

Asked by Akshada Deo

2 min read 7 chapters

Detailed narrative

Q1 FY26 Financial Performance Overview

Tatva Chintan reported a robust Q1 FY26 with operating revenue reaching INR 1,169 million, marking an 11% year-on-year and 8% quarter-on-quarter increase. EBITDA surged to INR 173 million, reflecting a significant 37% year-on-year and 94% quarter-on-quarter growth. This strong performance led to an EBITDA margin expansion of 287 basis points year-on-year, reaching 14.8%, while PAT grew 26.9% YoY to INR 66 million.

Segmental Business Performance

The Pharma & Agro Intermediates and Specialty Chemicals (PASC) segment was a key growth driver, delivering INR 432 million in revenue, up 32% sequentially and 11% year-on-year. The Structure Directing Agents (SDA) segment also performed well, recording INR 394 million with 14% QoQ and 13% YoY growth. However, the Phase Transfer Catalyst (PTC) segment saw a 17% decline QoQ to INR 323 million, though it grew 9% YoY. Electrolyte Salts revenue increased 32% QoQ to INR 12 million, despite a 12% YoY dip.

Strategic Focus on R&D and Innovation

Management reiterated its core focus on strengthening R&D capabilities, emphasizing scientific innovation as the most sustainable path to value creation. This approach is gaining recognition from customers, leading to interesting developmental opportunities. The company believes its strategic investments and customer-centric approach are well-aligned to capture long-term growth across critical markets.

Progress in New Product Commercialization

Tatva Chintan is actively commercializing new products across segments. A new large agro intermediate is continuously being manufactured for Q3 orders, and a second agro intermediate has received commercial approval for supply starting in H2 FY26. In the semiconductor segment, successful pilot scale samples have been delivered, with slow commercialization expected to begin in 2027 and full-scale by 2029.

SDA Segment Outlook and Euro 7 Norms

The SDA segment is experiencing a revival in demand, with increased visibility from key customers. Management expects continued revenue growth in coming quarters, supported by the upcoming implementation of Euro 7 norms. Orders for Euro 7 supplies are beginning from October, positioning this segment for significant growth, despite current pricing remaining at non-viable levels due to raw material costs.

Electrolyte Salts and Energy Storage Market

The Electrolyte Salts segment is seeing a steady uptick from customers using its products in energy storage devices. The second approved product is being manufactured for dispatch this quarter, and a new customer for hybrid vehicles has approved material for extended validations. The company aims for this segment to contribute roughly 10% to the top line in the next financial years, with potential revenue of INR 15-20 crores from existing facilities.

CFO Transition and Management Outlook

The company announced the departure of its CFO, Mr. Ashok Bothra, who is relocating for another opportunity. Despite this change and persistent global geopolitical uncertainties, management expressed cautious optimism, noting a gradual recovery in export markets. They are confident in sustaining growth and delivering consistent performance in the quarters ahead, with clear visibility of orders until at least December.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls